Socio Today
The Indonesian Association of Dermatology and Venereology (PERDOSKI) has officially addressed a rapidly growing viral trend surrounding advanced cosmetic skin boosters originating from South Korea, colloquially dubbed by internet users as "corpse skin" injections. These specialized aesthetic treatments fundamentally rely on Human Acellular Dermal Matrix (hADM) as their primary raw material. While South Korean cosmetic laboratories market these products as revolutionary anti-aging and skin-regenerating solutions, social media platforms have been flooded with intense public speculation, ethical debates, and misinformation regarding the literal harvesting of human skin from deceased individuals. As these products continue to infiltrate international markets through gray-market channels and specialized aesthetic clinics, dermatological authorities in Indonesia are stepping forward to clarify the medical realities, ethical frameworks, and regulatory requirements governing such controversial biotechnological innovations.
The controversy gained significant traction across global and domestic social media platforms as beauty influencers and consumers began discussing the microscopic composition of hADM-based injectables. The term "corpse skin" quickly trended, provoking widespread apprehension among prospective patients who questioned the safety, hygiene, and ethical sourcing of ingredients utilized in routine dermatological procedures. In response to the escalating public anxiety, the Chairperson of the Central Executive Board of PERDOSKI, Dr. dr. Hanny Nilasari, Sp.DVE, Subsp.Ven, FINSDV, FAADV, provided an authoritative clarification during an exclusive media interview. Dr. Hanny confirmed that the foundational material utilized in these specific skin boosters indeed originates from human tissue donations. However, she emphasized that sweeping generalizations labeling the treatment as "corpse skin injections" are scientifically inaccurate, misleading, and fail to capture the complex biomedical processing involved in manufacturing cellular matrices.
According to dermatological science and tissue-banking standards, Human Acellular Dermal Matrix is derived by stripping human donor skin of all cellular components, leaving behind only the structural extracellular matrix, predominantly composed of collagen. This acellular framework is designed to act as a scaffold that promotes tissue regeneration, cellular ingrowth, and structural repair. Despite this scientific definition, Dr. Hanny pointed out a critical transparency gap regarding the exact provenance of the harvested tissue. PERDOSKI noted that the medical community in Indonesia—and globally—remains uncertain whether the source material is harvested exclusively from living donors undergoing reconstructive surgeries, such as abdominoplasties, or from cadaveric tissue donations regulated by tissue banks. This ambiguity has fueled further speculation and heightened the urgency for rigorous scientific scrutiny before such products can be safely integrated into standard Indonesian aesthetic practices.
Chronology of the Trend and Regulatory Response
The infiltration of hADM-based skin boosters into the broader Asian beauty market represents a convergence of advanced regenerative medicine and the booming medical tourism industry centered in Seoul, South Korea. Over the past several years, South Korean biotechnology firms have pioneered the adaptation of medical-grade reconstructive materials into aesthetic dermatology. Originally utilized extensively in severe burn treatments, periodontal grafting, and breast reconstruction, dermal matrices began finding their way into cosmetic skin rejuvenation protocols around 2023 and 2024. These treatments promised enhanced dermal thickness, prolonged elasticity, and superior tissue healing compared to traditional hyaluronic acid fillers.
By late 2025 and into early 2026, international travelers visiting South Korean aesthetic clinics began documenting their experiences with these advanced skin boosters on platforms like TikTok, Instagram, and YouTube. The translation of marketing materials mentioning "human-derived dermal matrix" quickly morphed into sensationalized terminology among English- and Indonesian-speaking netizens, giving birth to the viral "corpse skin" narrative. As aesthetic clinics in major Indonesian metropolitan areas like Jakarta, Surabaya, and Bali began receiving inquiries from affluent clients requesting these specific South Korean formulations, domestic dermatologists recognized the urgent need for an official institutional stance.
In mid-September 2026, PERDOSKI formally initiated internal reviews regarding the influx of hADM products. Dr. Hanny Nilasari’s public statements on September 16, 2026, marked the first official institutional response from Indonesia’s premier governing body for dermatologists. PERDOSKI’s intervention aimed to halt the spread of unverified panic while simultaneously placing strict procedural roadblocks in front of practitioners tempted to import or administer unapproved regenerative injectables without adequate clinical backing.
Scientific and Technical Context of Human Acellular Dermal Matrix
To understand the gravity of PERDOSKI’s cautionary stance, it is essential to examine the clinical nature of Human Acellular Dermal Matrix and its traditional applications in modern medicine. hADM is not a cosmetic creation; it is a sophisticated biological product developed through rigorous decellularization protocols. In reconstructive surgery, donor human skin—sourced either from living donors who consent to tissue donation during elective surgeries or from deceased donors through accredited tissue banks—undergoes chemical and enzymatic processing. This process removes all cellular material, including epidermal cells, fibroblasts, and vascular elements, along with DNA and RNA, which are the primary triggers of immune rejection and disease transmission.
What remains is a purified collagen and elastin matrix that provides a supportive structural framework. When implanted into human tissue, the host’s native cells gradually migrate into the matrix, laying down new blood vessels and collagen fibers in a process known as cellular integration and remodeling. In conventional medical settings, hADM has an exemplary safety record when used for complex procedures such as diabetic foot ulcer repairs, deep burn wound coverings, hernia repairs, and post-mastectomy breast reconstructions.
However, translating a reconstructive scaffold meant for surgical implantation into a micro-needled or superficial injectable skin booster designed for general anti-aging represents a significant paradigm shift. Dr. Hanny highlighted that up to the present day, there remains a distinct scarcity of peer-reviewed scientific literature detailing the specific manufacturing techniques, micronization processes, and clinical efficacy trials for hADM products specifically formulated as superficial cosmetic skin boosters. Without transparent, publicly accessible data on how these matrices are broken down into injectable particles and how they interact with the dynamic immune environment of facial skin, dermatological associations must exercise extreme caution.
Regulatory Standards and Patient Safety in Indonesia
The deployment of any foreign medical or aesthetic product within the jurisdiction of the Republic of Indonesia is strictly regulated by the Indonesian Food and Drug Authority (BPOM – Badan Pengawas Obat dan Makanan), alongside compliance with medical ethics codes enforced by the Indonesian Medical Association (IDI) and specialty boards like PERDOSKI. When evaluating novel medical technologies, regulatory frameworks prioritize three fundamental pillars: patient safety, legal compliance, and material transparency.
Patient safety is paramount. In dermatological practice, introducing animal-derived, synthetic, or human-derived biological products carries inherent risks of allergic reactions, granuloma formation, chronic inflammatory responses, and, in worst-case scenarios, the transmission of infectious agents if viral inactivation protocols are compromised. While tissue banks in developed nations adhere to stringent screening protocols for HIV, hepatitis, and other blood-borne pathogens, the global supply chain for aesthetic injectables is increasingly vulnerable to counterfeit products, gray-market importation, and unverified manufacturing facilities operating outside international standards.
Legal compliance and material transparency are equally critical bottlenecks for hADM skin boosters in Indonesia. Dr. Hanny explicitly emphasized that PERDOSKI cannot endorse or greenlight treatments that lack full disclosure regarding their supply chain, donor consent verification, and regulatory clearance from the country of origin and BPOM.
"And then if it is in Indonesia itself, of course, we need patient safety, patient safety for those we treat, then legality, then transparency of the materials we use," Dr. Hanny stated during her briefing. "Perhaps if all of those things have been fulfilled, we can see whether it can be approved to enter Indonesia."
This stance reflects a protective regulatory posture designed to shield Indonesian consumers from experimental procedures marketed under the guise of established medical science. Until manufacturers provide exhaustive documentation proving that their products meet international biological safety standards and secure official BPOM marketing authorization, Indonesian dermatologists affiliated with PERDOSKI are ethically bound to refrain from utilizing these specific treatments.
Broader Implications and Future Outlook for Aesthetic Dermatology
The controversy surrounding hADM skin boosters underscores a broader philosophical and ethical tension within the global multi-billion-dollar aesthetic medicine industry. As consumers demand increasingly potent, regenerative anti-aging solutions—moving beyond traditional hyaluronic acid fillers and botulinum toxin toward stem-cell therapies, exosomes, and human tissue derivatives—the boundaries between corrective reconstructive surgery and vanity-driven cosmetic enhancement are becoming increasingly blurred.
This trend raises profound bioethical questions regarding the commodification of human tissue. While the medical community has long accepted human tissue donation for life-saving organ transplants and sight-restoring corneal grafts, expanding the human tissue economy to supply routine anti-aging skin boosters for affluent consumers introduces complex ethical dilemmas. Questions regarding informed consent—specifically whether a donor or their grieving family would consent to their biological tissues being utilized for commercial skin rejuvenation—remain a grey area in international bioethics, particularly when tissues are exported across international borders through commercial supply chains.
Furthermore, the economic implications for the Indonesian domestic aesthetic market are significant. South Korea remains a dominant trendsetter in Asian beauty standards, and viral social media trends frequently create intense consumer demand that outpaces local regulatory approvals. This dynamic often fosters a shadow market where unlicensed practitioners or unauthorized clinics attempt to smuggle trending products into the country, bypassing BPOM oversight and putting patients at severe risk of medical complications.
By taking a firm, evidence-based stance, PERDOSKI aims to establish a clear boundary between responsible medical practice and unverified aesthetic fads. The association’s insistence on rigorous clinical trials, transparent material sourcing, and strict legal compliance serves as a vital safeguard for the Indonesian public. As regenerative medicine continues to evolve, the medical community faces the ongoing challenge of balancing the desire for cutting-edge innovation with uncompromising standards of safety, ethics, and transparency. Until hADM skin boosters can clear these rigorous scientific and regulatory hurdles, Indonesian consumers are advised to approach viral cosmetic trends with healthy skepticism and rely on clinically validated, approved treatments administered by certified dermatology specialists.
